Ahead of adcomm, FDA raises concerns about plan to expand Lynparza's use in prostate cancer
The FDA’s Oncologic Drugs Advisory Committee will discuss AstraZeneca and Merck’s application to expand the use of their drug Lynparza to all adults with prostate …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
